[Reversible neuropsychological deterioration associated to zonisamide in a paediatric patient with tuberous

M Concepción Fournier-Del Castillo1, Javier Melero-Llorente, Miriam Blanco-Beregana

  • 1Hospital Infantil Universitario Nino Jesus, 28009 Madrid, Espana.

Revista De Neurologia
|January 14, 2015
PubMed

Insights

High doses of zonisamide caused temporary cognitive decline in a child with epilepsy. Stopping the drug improved cognitive function, distinguishing drug effects from epilepsy impacts.

Area of Science:

  • Neuroscience
  • Pediatric Neurology
  • Epileptology

Background:

  • Tuberous sclerosis complex (TSC) is a genetic disorder that can cause epilepsy.
  • Refractory epilepsy often requires surgical evaluation.
  • Neuropsychological assessments are crucial for evaluating cognitive function in epilepsy patients.

Observation:

  • A case study of an 11-year-old boy with TSC and refractory left frontal epilepsy.
  • High-dose zonisamide treatment was associated with cognitive deterioration.
  • The Reliable Change Index was used to control for practice effects in assessments.

Findings:

  • Zonisamide-induced cognitive deficits mimicked effects of the epileptogenic zone on the language-dominant hemisphere.
  • Drug withdrawal led to significant improvements in overall intelligence, verbal comprehension, and language-related cognitive abilities.
  • These improvements were observed beyond the expected practice effects from repeated testing.

Implications:

  • Distinguishing drug-induced cognitive side effects from epilepsy-related deficits is critical for surgical decision-making.
  • Careful medication management is essential in pediatric epilepsy patients undergoing presurgical evaluation.
  • This case highlights the importance of comprehensive neuropsychological monitoring during epilepsy treatment.
Abstract

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
1.0K
Desensitization and Tachyphylaxis01:20

Desensitization and Tachyphylaxis

Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
3.5K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
391
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
371
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.2K
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.8K